Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We employ our advanced, specialised process to create targeted libraries for receptors.


 

Fig. 1. The screening workflow of Receptor.AI

This process includes extensive molecular simulations of the receptor in its native membrane environment, along with ensemble virtual screening that accounts for its conformational mobility. In the case of dimeric or oligomeric receptors, the entire functional complex is modelled, identifying potential binding pockets on and between the subunits to encompass all possible mechanisms of action.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P56373

UPID:
P2RX3_HUMAN

ALTERNATIVE NAMES:
ATP receptor; Purinergic receptor

ALTERNATIVE UPACC:
P56373; Q6DK37; Q9UQB6

BACKGROUND:
The P2X purinoceptor 3, recognized alternatively as ATP receptor or Purinergic receptor, serves as a crucial component in sensory perception mechanisms. It operates as a ligand-gated cation channel, triggered by ATP, to mediate ion transport. This receptor's involvement is vital for the accurate perception of pain and taste, underscoring its significance in sensory functions.

THERAPEUTIC SIGNIFICANCE:
Exploring the functionalities of P2X purinoceptor 3 paves the way for innovative therapeutic approaches. Given its integral role in the perception of pain, targeting this receptor could lead to breakthroughs in pain relief treatments, providing new avenues for alleviating chronic pain syndromes.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.